'Blockbuster brands may run into intense competition from generics'

摘要

Despite being the current gold standard and sales heavyweight of the antipsychotic market,with US 4-bn in global sales,Eli Lilly's Zyprexa(olanzapine)is facing legal action in the US over alleged side effects and along with other blockbuster drugs in the market,may also run into intense competition from generics earlier than expected,according to a new report by independent market analyst Datamonitor.Today,the antipsychotic market is one of the largest and most commercially attractive CNS markets,with annual revenues of US10.4-bn in 2003 and a growth rate of 24.1 %,says Datamonitor CNS analyst Alistair Sinclair."